Therachon
Aug 10, 2018
Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup
Sarepta builds in gene therapy with $30M Lacerta deal Sarepta has dampen its enthusiasm for an ongoing gene therapy candidate. Sarepta has made a tie-up with lacerta that will add 3 more programs to 8 already existing and are ready to expand its focus beyond muscular dystrophy. Sarepta has committed to pay Lacerta ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
